KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 3 filers reported holding KALA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,000 | -25.0% | 12,270 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -77.8% | 12,270 | -3.7% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 12,745 | -19.1% | 0.00% | – |
| Q4 2021 | $20,000 | -45.9% | 15,745 | +10.5% | 0.00% | – |
| Q3 2021 | $37,000 | -35.1% | 14,245 | +32.3% | 0.00% | – |
| Q2 2021 | $57,000 | +216.7% | 10,770 | +310.3% | 0.00% | – |
| Q1 2021 | $18,000 | +50.0% | 2,625 | +64.1% | 0.00% | – |
| Q3 2020 | $12,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,430,021 | $9,638,000 | 6.26% |
| RA Capital Management | 10,874,613 | $73,295,000 | 1.10% |
| Mesirow Financial Investment Management, Inc. | 41,961 | $283,000 | 0.77% |
| Samsara BioCapital, LLC | 601,162 | $4,052,000 | 0.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $689,000 | 0.38% |
| Eventide Asset Management | 3,450,000 | $23,253,000 | 0.34% |
| Orbimed Advisors | 5,465,030 | $36,834,000 | 0.34% |
| Parkman Healthcare Partners LLC | 148,433 | $1,000,000 | 0.23% |
| Vivo Capital, LLC | 786,883 | $5,304,000 | 0.19% |
| Knights of Columbus Asset Advisors LLC | 199,954 | $1,348,000 | 0.13% |